Evolution of the health economics of cervical cancer vaccination

Nicole Ferko, Maarten Postma, Steve Gallivan, Denise Kruzikas, Michael Drummond

Research output: Contribution to journalLiterature reviewpeer-review

Abstract

This paper reviews the history of modelling for cervical cancer vaccination. We provide an interpretation and summary of conclusions pertaining to the usefulness of different models, the predicted epidemiological impact of vaccination and the cost-effectiveness of adolescent, catch-up and sex-specific vaccination strategies. To date, model results predict a critical role for vaccination in reducing the burden of cervical disease, with cost-effectiveness being consistently shown across studies using a common threshold of US $50,000 per QALY, but further clinical and epidemiological data are required to confirm these findings. Through this paper, we aim to provide useful insights for decision-makers as they examine how to best evaluate the potential impact of vaccines against cervical cancer and determine how to best incorporate vaccination into practice. (C) 2008 Elsevier Ltd. All rights reserved.

Original languageEnglish
Pages (from-to)F3-F15
Number of pages13
JournalVaccine
Volume26
Issue numberSUPPL.5
DOIs
Publication statusPublished - 15 Sept 2008

Keywords

  • HPV
  • vaccines
  • modelling
  • HUMAN-PAPILLOMAVIRUS VACCINATION
  • RANDOMIZED CONTROLLED-TRIAL
  • NATURAL-HISTORY MODEL
  • LIQUID-BASED CYTOLOGY
  • COST-EFFECTIVENESS
  • PARTICLE VACCINE
  • SCREENING-PROGRAMS
  • YOUNG-WOMEN
  • HPV INFECTION
  • DOUBLE-BLIND

Cite this